We see so few papers on resistance to thyroid hormone, it seems appropriate to post when one does arrive.
I have no explanation whatsoever for every-other-day liothyronine therapy being potentially worth trying. But it does make me think of the fact that Dr Lowe went down the one-dose-a-day route - very much against the little-and-often approach often suggested.
BMC Endocr Disord. 2016 Jan 12;16(1):1. doi: 10.1186/s12902-015-0081-7.
Successful every-other-day liothyronine therapy for severe resistance to thyroid hormone beta with a novel THRB mutation; case report.
Maruo Y1, Mori A2, Morioka Y3, Sawai C4, Mimura Y5, Matui K6, Takeuchi Y7.
Author information
1 Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, 520-2192, Japan. maruo@belle.shiga-med.ac.jp.
2 Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, 520-2192, Japan. asamim@belle.shiga-med.ac.jp.
3 Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, 520-2192, Japan. yori708@belle.shiga-med.ac.jp.
4 Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, 520-2192, Japan. csawai@belle.shiga-med.ac.jp.
5 Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, 520-2192, Japan. osawa@belle.shiga-med.ac.jp.
6 Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, 520-2192, Japan. matsui@belle.shiga-med.ac.jp.
7 Department of Pediatrics, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, 520-2192, Japan. takeuchi@belle.shiga-med.ac.jp.
Abstract
BACKGROUND:
Resistance to thyroid hormone beta (RTHβ) is a rare and usually dominantly inherited syndrome caused by mutations of the thyroid hormone receptor β gene (THRB). In severe cases, it is rarely challenging to control manifestations using daily therapeutic replacement of thyroid hormone.
CASE PRESENTATION:
The present case study concerns an 8-year-old Japanese girl with a severe phenotype of RTH (TSH, fT3, and fT4 were 34.0 mU/L, >25.0 pg/mL and, >8.0 ng/dL, respectively), caused by a novel heterozygous frameshift mutation in exon 10 of the thyroid hormone receptor beta gene (THRB), c.1347-1357 del actcttccccc : p.E449DfsX11. RTH was detected at the neonatal screening program. At 4 years of age, the patient continued to suffer from mental retardation, hyperactivity, insomnia, and reduced resting energy expenditure (REE), despite daily thyroxine (L-T4) therapy. Every-other-day high-dose liothyronine (L-T3) therapy improved her symptoms and increased her REE, without thyrotoxicosis.
CONCLUSION:
In a case of severe RTH, every-other-day L-T3 administration enhanced REE and psychomotor development, without promoting symptoms of thyrotoxicosis. Every-other-day L-T3 administration may be an effective strategy for the treatment of severe RTH.
PMID: 26754848 [PubMed - in process]